

Metodi V Stankov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8617854/publications.pdf>

Version: 2024-02-01

34
papers

1,547
citations

430442

18
h-index

377514

34
g-index

40
all docs

40
docs citations

40
times ranked

3385
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9
2	Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. <i>HIV Medicine</i> , 2022, 23, 558-563.	1.0	47
3	Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2. <i>Peritoneal Dialysis International</i> , 2022, 42, 100-101.	1.1	10
4	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 863039.	2.2	10
5	Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination. <i>Emerging Infectious Diseases</i> , 2022, 28, 743-750.	2.0	18
6	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. <i>Cell Reports</i> , 2022, 39, 110754.	2.9	5
7	SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study. <i>BMC Infectious Diseases</i> , 2022, 22, 403.	1.3	10
8	COVID-19 immune signatures reveal stable antiviral T _H 1 cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
9	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
10	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
11	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
12	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. <i>EBioMedicine</i> , 2021, 70, 103524.	2.7	53
13	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 37, 109825.	2.9	73
14	SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. <i>Lancet</i> , 2021, 398, 1041-1042.	6.3	24
15	Alpha1-antitrypsin counteracts heme-induced endothelial cell inflammatory activation, autophagy dysfunction and death. <i>Redox Biology</i> , 2021, 46, 102060.	3.9	6
16	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	4.8	25
17	Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2557-2559.	4.8	41
18	Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?. <i>Frontiers in Medicine</i> , 2021, 8, 770381.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. <i>Infectious Diseases and Therapy</i> , 2020, 9, 837-849.	1.8	34
20	Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. <i>Infection</i> , 2020, 48, 631-634.	2.3	69
21	HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway. <i>Cell Death and Disease</i> , 2019, 10, 235.	2.7	19
22	Zidovudine-Mediated Autophagy Inhibition Enhances Mitochondrial Toxicity in Muscle Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	10
23	Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8 ⁺ T cell proliferation. <i>European Journal of Immunology</i> , 2018, 48, 2042-2054.	1.6	11
24	Herpes simplex virus 1 interferes with autophagy of murine dendritic cells and impairs their ability to stimulate CD8 ⁺ T lymphocytes. <i>European Journal of Immunology</i> , 2017, 47, 1819-1834.	1.6	26
25	Inhibition of Autophagic Flux by Salinomycin Results in Anti-Cancer Effect in Hepatocellular Carcinoma Cells. <i>PLoS ONE</i> , 2014, 9, e95970.	1.1	51
26	Thymidine Analogues Suppress Autophagy and Adipogenesis in Cultured Adipocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 543-551.	1.4	18
27	Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. <i>Aids</i> , 2012, 26, 1995-2006.	1.0	44
28	Contribution of Inflammation to Fat Redistribution and Metabolic Disturbances in HIV-1 Infected Patients. <i>Current Pharmaceutical Design</i> , 2010, 16, 3361-3371.	0.9	14
29	Mitochondrial DNA Depletion and Respiratory Chain Activity in Primary Human Subcutaneous Adipocytes Treated with Nucleoside Analogue Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 280-287.	1.4	38
30	Impact of Stimulatory Pathways on Adipogenesis and HIV-Therapy Associated Lipoatrophy. <i>Experimental Biology and Medicine</i> , 2009, 234, 1484-1492.	1.1	1
31	Combined effect of C-reactive protein and stavudine on adipogenesis. <i>Antiviral Therapy</i> , 2009, 14, 819-829.	0.6	5
32	Zidovudine Impairs Adipogenic Differentiation through Inhibition of Clonal Expansion. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2882-2889.	1.4	22
33	Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. <i>Antiviral Therapy</i> , 2007, 12, 205-16.	0.6	16
34	Relationship of Mitochondrial DNA Depletion and Respiratory Chain Activity in Preadipocytes treated with Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2007, 12, 205-216.	0.6	27